ArticleResearch involvement and engagement2025
Perspective on patient and non-academic partner engagement for the responsible integration of large language models in health chatbots.
Article in Research involvement and engagement, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uses of large language models (LLMs) in health chatbots are expanding into high-stakes clinical contexts, heightening the need for tools that are evidence-based, accountable, accurate, and patient-centred. This conceptual, practice-informed Perspective reflects on engaging patients and non-academic partners for the responsible integration of LLMs, grounded in the co-construction of MARVIN (for people living with HIV) and in an emerging collaboration with MIT Critical Data. Organised by the Software Development Life Cycle, we describe: conception/needs assessment with patient partners to identify use cases, acceptable trade-offs, and privacy expectations; development that prioritises grounding via vetted sources, structured human feedback, and data-validation committees including patient partners; testing and evaluation using patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) chosen in collaboration with patients to capture usability, acceptability, trust, and perceived safety, alongside task performance and harmful-output monitoring; and implementation via diverse governance boards, knowledge-mobilisation materials to set expectations, and risk-management pathways for potentially unsafe outputs. Based on our experience with MARVIN, we recommend early and continuous engagement of patients and non-academic partners, fair compensation, shared decision-making power, transparent decision logging, and inclusive, adaptable governance that can evolve with changing models and standards. These lessons highlight how patient partnership can directly shape chatbot design and oversight, helping teams align LLM-enabled tools with patient-centred goals while building accountable, safe, and equitable systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.